Greenwich LifeSciences, Inc.
GLSI
$9.25
-$0.61-6.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -8.04M | -2.67M | -2.61M | -2.47M | -2.75M |
| Total Depreciation and Amortization | 900.00 | 900.00 | 900.00 | 900.00 | 900.00 |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.47M | 594.50K | 594.50K | 594.50K | 594.50K |
| Change in Net Operating Assets | 717.30K | -510.60K | 963.40K | 95.20K | -2.90K |
| Cash from Operations | -1.85M | -2.58M | -1.05M | -1.78M | -2.15M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 121.80K | 1.18M | 2.77M | 299.10K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 121.80K | 1.18M | 2.77M | 299.10K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.73M | -1.40M | 1.72M | -1.48M | -2.15M |